BEIGF - BeOne Medicines outlines $5B-$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates
2025-08-06 13:37:33 ET
More on BeiGene
- BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
- BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
- BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
- BeiGene Q2 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on BeiGene